Akebia Therapeutics (AKBA)
(Real Time Quote from BATS)
$1.39 USD
+0.04 (2.96%)
Updated Aug 15, 2024 10:52 AM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKBA 1.39 +0.04(2.96%)
Will AKBA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Other News for AKBA
Akebia price target raised by $1.50 at H.C. Wainwright, here's why
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript
Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)
Akebia Therapeutics: Q2 Earnings Snapshot
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights